Transfusion therapy remains an important treatment modality for patients with sickle cell disease (SCD). Despite its therapeutic benefits, red blood cell transfusion results in the development of antibodies against disparate antigens on transfused red cells (alloimmunization) in approximately 20–50% of patients with SCD. Alloantibodies can cause delayed hemolytic transfusion reactions, which in SCD patients can trigger hyperhemolysis, a life-threatening poorly understood phenomenon in which the transfused and the patient’s own red blood cells are destroyed.1 In addition, finding compatible units for patients with alloantibodies can be difficult, causing potentially life-threatening transfusion delays. Matching for key immunogenic antigens disparate between patients (of African ancestry) and blood donors (mostly white), namely Rh-C, -E and K, has been a strategy used to reduce alloimmunization in patients with SCD; however, patients transfused with C,E,K-matched donor RBC (from mostly black donors), can still develop pathogenic Rh antibodies due to the genetic diversity of the RH locus in individuals of African ancestry.2,3 This highlights the need for better characterization of alloimmunization triggers and risk factors/biomarkers in this highly vulnerable population.
The etiology of alloimmunization in patients with SCD remains unclear. Our group has recently studied antigen-specific CD4 helper T-cell responses in peripheral blood of transfused patients with SCD.4 We found that in alloantibody responder patients, antigen-specific CD4 T-cell responses were predominantly TH17, and that interleukin (IL)-21, the prototypic follicular helper T-cell (TFH)-associated cytokine driving B-cell help, was only expressed by antigen-specific TFH derived from responders.4 These data are consistent with the role of heightened CD4 T-cell effector functions driving alloantibody production in alloimmunized SCD patients.
TFH cells have emerged as the main effector CD4 T cells specialized in providing help to support responses of antigen-engaged B cells to generate the initial wave of antibody response as well as in supporting B-cell differentiation into high affinity antibody-producing B cells and long-lasting IgG antibodies.5 TFH cells are universally characterized by: (i) the expression of the chemokine (C-X-C motif) receptor 5 (CXCR5) on memory (CD45RA) cells which directs them to the B-cell follicles in response to the specific ligand CXCL13;6–8 (ii) expression of IL-21, a potent cytokine promoting growth, differentiation, and class switching of B cells although they also secrete other B-cell help cytokines including IL-4;9,10 and (iii) co-stimulatory molecules specialized in providing B-cell help including inducible T-cell co-stimulatory (ICOS) and CD40L.5,11 Given the key role of TFH cells in providing help to B cells to support their activation, expansion and differentiation, these cells have attracted particular attention as potential targets for developing therapeutic strategies not only to enhance vaccination responses but also to prevent antibody-mediated autoimmunity.5 Our studies of antigen-specific TFH responses in alloimmunized SCD patients support the notion that TFH cells are also likely to be critical in alloimmunization biology.4 More recently, TFH-related cells with ability to promote antibody responses were identified in the peripheral circulation of humans and mice,12–19 opening up the possibility of studying TFH cell responses in blood samples.
In the report from Yazdanbakhsh’s group published in this issue of the journal,20 Godefroy et al. examine the role of two immune checkpoints21 expressed by CD4/CD45RA/CXCR5 circulating follicular helper T (cTFH) cells: the programmed cell death-1 (PD-1) and the T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory domains (TIGIT) surface molecules. The function of PD-1 on TFH cells remains controversial and has been described as both promoting15,16 and reducing17,22,23 humoral responses in different models. The recent discovery of regulatory follicular T cells (TFR) expressing high levels of PD-117 may help to reconcile these divergent findings. Although TIGIT expression on T cells has been studied previously,24–29 the function of TIGIT on TFH cells is being addressed for the first time in the study by Godefroy et al.20
The authors show that TIGIT-expressing cells represent almost half of the cTFH population, while PD-1 cells, all co-expressing TIGIT, are significantly less frequent, accounting for about 9% of the cTFH cells.20 Several subsets of cTFH have previously been characterized. Three main subsets, named TFH1, TFH2 and TFH17, can be identified not only by their ability to produce type 1, 2 and 17 cytokines or express their respective transcription factors (T-bet, GATA3, RORc), but also by their expression of chemokine receptors CXCR3 and CCR6.13 TFH1 cells express CXCR3, but not CCR6; TFH2 cells express neither; TFH17 cells express CCR6, but not CXCR3.13 Based on chemokine receptor expression, the authors show that TIGIT cTFH represent a subset phenotypically different from any of the three populations previously described.20 Interestingly, TIGIT cTFH can produce IL-4 and to some extent interferon-gamma. Accordingly, both TFH1 and TFH2 can be found in TIGIT cTFH independently of the cells’ PD-1 expression.20 IL-17 secretion was not tested. Nonetheless, these findings establish that TIGIT cells, whether or not they express PD-1, represent a novel subset of cTFH.
Importantly, TIGIT cTFH cells exerted strong B-cell help functions.20 Compared to TIGIT cTFH, they were able to better promote differentiation of B cells into plasmablasts and IgG-producing cells.20 Furthermore, the study of sorted cTFH subsets showed that TIGIT/PD-1 cells provide similar help to B cells as TIGIT/PD-1 cells,20 suggesting that PD-1 plays a limited role in promoting humoral responses in this model. Despite the fact that it still needs to be proven, TIGIT cTFH cells heightened help to B cells probably lie in their enhanced expression of CD40L and ICOS co-stimulation molecules and/or their capacity to produce large amounts of IL-21. Alternatively, B-cell help could be provided directly by signaling through TIGIT’s ligand(s). Whether TIGIT cTFH cells influence isotype switching of Ig production, as shown for TFH2 and TFH17, remains to be determined.
Using blocking antibodies, Godefroy et al. also demonstrated that whereas PD-1 did not seem to play a major role in this system, TIGIT was directly implicated in the function of these cells.20 Indeed, blocking TIGIT not only decreased the expression levels of ICOS, CD40L and IL-21, but also prevented B cells from producing IgG.10 Other authors proposed a direct role for PD-1 in TFH function.15–17,22,23 In the study by Godefroy et al., the authors did not observe a significant effect after blocking PD-1.20 This could be due to the use of different experimental systems or a mixture of opposite effects mediated by PD-1 cancelling each other. Instead, the fact that all PD-1 cTFH co-express TIGIT20 could suggest that PD-1 represents a non-functional marker on cTFH and that TIGIT/PD-1 cTFH B-cell help functions are due, at least in part, to TIGIT.
The study suggests a role for TIGIT-expressing cTFH cells in alloimmunization in the context of SCD.20 In alloimmunized patients, TIGIT cTFH cells offered more potent help to B cells than in non-alloimmunized patients: IL-21 and CD40L expression was higher in alloimmunized patients than in non-alloimmunized patients.20 This could be explained either by faulty TIGIT signaling in non-alloimmunized patients or by an exacerbated response to TIGIT triggering in alloimmunized patients. Collectively, these data suggest involvement of various subsets of cTFH cells displaying different functions in the alloimmunization process of SCD patients.
Chronic antigen stimulation can result in T-cell exhaustion associated with lack of cytotoxic activity and failure to produce type 1 cytokines, interferon-gamma and IL-2 as well as up-regulation of several immune checkpoint molecules including TIGIT on the exhausted T cells.21 Godefroy et al. propose an interesting model in which repeated exposure to allogeneic red blood cells in patients with SCD could lead to exhaustion of red blood cell-specific T cells, which would end up triggering the expression of immune checkpoints such as TIGIT. This brings into question whether exhausted type 1 CD4 T cells could be skewed towards a TFH phenotype by expressing TIGIT (or other “exhaustion” markers) after repeated stimulation caused by chronic transfusions. Considering the latter question from a non-transfusion perspective, the authors propose an interesting hypothesis: if chronic stimulation induces TH1 or TFH1 cells to differentiate into TFH cells, could this process reflect an evolutionary mechanism by which TIGIT would be involved in reducing type 1 chronic inflammation as well as shifting immune responses from cellular to potentially more “suitable”, humoral responses?
Overall, these studies provide new insight into TFH polarization, and help give rise to the development of therapeutic strategies, not only regarding alloimmunization, but also in vaccination as well as in a large array of disorders, including inflammatory diseases, autoimmunity and immune deficiencies.
Footnotes
- Financial and other disclosures provided by the author using the ICMJE (www.icmje.org) Uniform Format for Disclosure of Competing Interests are available with the full text of this paper at www.haematologica.org.
References
- Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012; 120(3):528-537. PubMedhttps://doi.org/10.1182/blood-2011-11-327361Google Scholar
- Chou ST, Jackson T, Vege S. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013; 122(6):1062-1071. PubMedhttps://doi.org/10.1182/blood-2013-03-490623Google Scholar
- Silvy M, Tournamille C, Babinet J. Red blood cell immunization in sickle cell disease: evidence of a large responder group and a low rate of anti-Rh linked to partial Rh phenotype. Haematologica. 2014; 99(7):e115-117. PubMedhttps://doi.org/10.3324/haematol.2014.104703Google Scholar
- Vingert B, Tamagne M, Habibi A. Phenotypic differences of CD4(+) T cells in response to red blood cell immunization in transfused sickle cell disease patients. Eur J Immunol. 2015; 45(6):1868-1879. PubMedhttps://doi.org/10.1002/eji.201445187Google Scholar
- Crotty S. Follicular helper CD4 T cells (TFH). Ann Rev Immunol. 2011; 29:621-663. PubMedhttps://doi.org/10.1146/annurev-immunol-031210-101400Google Scholar
- Breitfeld D, Ohl L, Kremmer E. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med. 2000; 192(11):1545-1552. PubMedhttps://doi.org/10.1084/jem.192.11.1545Google Scholar
- Kim CH, Rott LS, Clark-Lewis I. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med. 2001; 193(12):1373-1381. PubMedhttps://doi.org/10.1084/jem.193.12.1373Google Scholar
- Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med. 2000; 192(11):1553-1562. PubMedhttps://doi.org/10.1084/jem.192.11.1553Google Scholar
- Bryant VL, Ma CS, Avery DT. Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. J Immunol. 2007; 179(12):8180-8190. PubMedhttps://doi.org/10.4049/jimmunol.179.12.8180Google Scholar
- Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity. 2009; 30(3):324-335. PubMedhttps://doi.org/10.1016/j.immuni.2009.03.003Google Scholar
- Choi YS, Kageyama R, Eto D. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity. 2011; 34(6):932-946. PubMedhttps://doi.org/10.1016/j.immuni.2011.03.023Google Scholar
- Bentebibel SE, Lopez S, Obermoser G. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med. 2013; 5(176):176ra32. PubMedhttps://doi.org/10.1126/scitranslmed.3005191Google Scholar
- Morita R, Schmitt N, Bentebibel SE. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011; 34(1):108-121. PubMedhttps://doi.org/10.1016/j.immuni.2010.12.012Google Scholar
- Chevalier N, Jarrossay D, Ho E. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol. 2011; 186(10):5556-5568. PubMedhttps://doi.org/10.4049/jimmunol.1002828Google Scholar
- He J, Tsai LM, Leong YA. Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity. 2013; 39(4):770-781. PubMedhttps://doi.org/10.1016/j.immuni.2013.09.007Google Scholar
- Locci M, Havenar-Daughton C, Landais E. Human circulating PD-(+)1CXCR3(−)CXCR5(+) memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity. 2013; 39(4):758-769. PubMedhttps://doi.org/10.1016/j.immuni.2013.08.031Google Scholar
- Sage PT, Francisco LM, Carman CV, Sharpe AH. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol. 2013; 14(2):152-161. PubMedhttps://doi.org/10.1038/ni.2496Google Scholar
- Saito R, Onodera H, Tago H. Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients. J Neuroimmunol. 2005; 170(1–2):172-178. PubMedhttps://doi.org/10.1016/j.jneuroim.2005.09.001Google Scholar
- Simpson N, Gatenby PA, Wilson A. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 2010; 62(1):234-244. PubMedhttps://doi.org/10.1002/art.25032Google Scholar
- Godefroy E, Zhong H, Pham P, Friedman D, Yazdanbakhsh K. TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. Haematologica. 2015; 100(11):1415-1425. Google Scholar
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-264. PubMedhttps://doi.org/10.1038/nrc3239Google Scholar
- Hams E, McCarron MJ, Amu S. Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells. J Immunol. 2011; 186(10):5648-5655. PubMedhttps://doi.org/10.4049/jimmunol.1003161Google Scholar
- Velu V, Titanji K, Zhu B. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009; 458(7235):206-210. PubMedhttps://doi.org/10.1038/nature07662Google Scholar
- Joller N, Hafler JP, Brynedal B. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol. 2011; 186(3):1338-1342. PubMedhttps://doi.org/10.4049/jimmunol.1003081Google Scholar
- Yu X, Harden K, Gonzalez LC. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009; 10(1):48-57. PubMedhttps://doi.org/10.1038/ni.1674Google Scholar
- Levin SD, Taft DW, Brandt CS. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 2011; 41(4):902-915. PubMedhttps://doi.org/10.1002/eji.201041136Google Scholar
- Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol. 2012; 188(8):3869-3875. PubMedhttps://doi.org/10.4049/jimmunol.1103627Google Scholar
- Yu X, Harden K, Gonzalez LC. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009; 10(1):48-57. PubMedhttps://doi.org/10.1038/ni.1674Google Scholar
- Yu X, Harden K, Gonzalez LC. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009; 10(1):48-57. PubMedhttps://doi.org/10.1038/ni.1674Google Scholar